Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-06-05
2007-06-05
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S380000, C530S324000, C530S827000
Reexamination Certificate
active
10947267
ABSTRACT:
The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus.
REFERENCES:
patent: 4857314 (1989-08-01), O'Connor et al.
patent: 5190917 (1993-03-01), Lezdey et al.
patent: 5290762 (1994-03-01), Lezdey et al.
patent: 5593897 (1997-01-01), Potempa et al.
patent: 5783179 (1998-07-01), Nestor et al.
patent: 6239099 (2001-05-01), Potempa
patent: 6331403 (2001-12-01), Potempa et al.
patent: 6342481 (2002-01-01), Leoni et al.
patent: 6528618 (2003-03-01), Fridkin et al.
patent: 6764826 (2004-07-01), Yeh et al.
patent: 2002/0119917 (2002-08-01), Fridkin et al.
patent: 2003/0171251 (2003-09-01), Pepys
patent: 92/06706 (1992-04-01), None
Bromwich E., British journal of cancer 91 (7) 1236-8, 2004.
Jabs Wolfram J., Kidney international 68 (5) 2103-10, 2005.
Szalai, AJ, et al., “Delayed Lupus Onset in (NZB x NZW)F1 mice Expressing a Human C-Reactive Protein Transgene,”Arthritis Rheum., 48(6):1602-11 (2003).—paper copy.
Xia, Dongyuan, et al., “Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia,”Proc. Natl. Acad. Sci. USA, 94:2575-2580 (1997).—paper copy.
Mortensen, Richard, et al., “Regulation of phagocytic leukocyte activities by C-reactive protein,”Journal of Leukocyte Biology, 67:495-500 (2000).—paper copy.
Gershov, Debra, et al., “C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains and anti-inflammatory innate immune response: Implications for systemic autoimmunity,”J. Exp. Med., 192(9): 1353-1363 (2000).—paper copy.
Hahn, Bevra H., “An overview of the pathogenesis of systemic lupus erythematosus,”Pathogenesis, pp. 87-96 (2002).—paper copy.
Gescuk, Bryan D. et al., “Novel therapeutic agents for systemic lupus erythematosus,”Curr. Opin. Rheumatol., 14:515-521 (2002).—paper copy.
Karpouzas, George et al., “Systemic lupus erythematosus,”Targeted Therapies in Rheumatology, J.S. Smolen and P.E. Lipsky editors, London, 563-581 (2003).—paper copy.
Volanakis, John E.,“Human C-reactive protein: expression, structure, and function,”Molecular Immunology, 38:189-197 (2001).—paper copy.
Heuertz, Rita M., “Inhibition of C5a des Arg-induced neutrophil alveolitis in transgenic mice expressing C-reactive protein,”Am. J. Phys., 266:L649-L654 (1994).—paper copy.
Du Clos, Terry et al., “Decreased autoantibody levels and enhanced survival of (NZB x NZW)F1 mice treated with C-Reactive Protein,”Clinical Immunology and Immunopathology, 70(1):22-27, (1994).—paper copy.
Du Clos, Terry et al., “Monoclonal antibody for DNA measurement in biological fluids,”J. of Immunological Methods, 88:185-192 (1986).—paper copy.
Theofilopoulos, Argyrios N. et al., “Murine Models of systemic lupus erythematosus,”Advances in Immunology, 37:269-391 (1985).—paper copy.
Spronk, P.E., “Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response?,”Annals of Rheumatic Diseases, 51:358-361 (1992).—paper copy.
Pepys, M. B. et al., “C-Reactive protein in SLE,”Clinics in Rheumatic Diseases, 8(1):91-103 (1982).—paper copy.
Baltz, Marilyn L. et al., “In vivo turnover studies of C-reactive protein,”,Clin. Exp. Immunol., 59:243-250 (1985).—paper copy.
Tipping, P. G. et al., “Immune Modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis,”Eur. J. Immunology, 27:530-537 (1997).—paper copy.
Kitching, Richard A. et al., “Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice,”Kidney International, 52:52-59 (1997).—paper copy.
Clynes R. et al., “Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis,”Science; 279: 1052-4 (1998).—on CD-ROM.
Du Clos, Terry, “C-reactive protein reacts with the U1 small nuclear ribonucleoprotein,”J. Immunol., 143(8):2553-9 (1989).—on CD-ROM.
Marnell L.L. et al., “C-reactive protein binds to Fc gamma RI in transfected COS cells,”J. Immunol., 155:2185-93 (1995).—CD-ROM.
Bharadwaj D. et al., “The major receptor for Creative protein on leukocytes is Fcgamma receptor II,”J Exp Med., 190:585-90 (1999).—on CD-ROM.
Mold C. et al. “C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R,”J Immunol., 169:7019-25 (2002).—CD-ROM.
Wakayama H., et al., “Abolition of anti-glomerular basement membrane antibody-mediated glomerulonephritis in FcR -deficient mice,”Eur J Immunol., 30:1182-90 (2002).—on CD-ROM.
Moore KW. et al., “Interleukin-10 and the Interleukin-10 receptor,”Ann Rev Immunol, 19:683-765 (2001).—on CD-ROM.
Du Clos TW, “Function of C-reactive protein,”Ann Med, 32:274-8 (2000).—on CD-ROM.
Robey FA., et al., “Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein,”J Biol Chem, 259(11):7311-6 (1984).—on CD-ROM.
Stein MP. et al., “C-reactive protein binding to murine leukocytes requires Fc gamma receptors,”J. Immunol, 164:1514-20 (2000).—on CD-ROM.
Walport MJ, “Lupus, DNase and defective disposal of cellular debris,”Nat Genet, 25: 135-6 (2000).—on CD-ROM.
Carroll MC., “A protective role for innate immunity in autoimmune disease,”Clin Immunol, 95(1):S30-8 (2000).—on CD-ROM.
Du Clos TW, “C-reactive protein as a regulator of autoimmunity and inflammation,”Arthritis Rheum, 48:1475-7 (2003).—on CD-ROM.
Xia D, Samols D, “Transgenic mice expressing rabbit C-reactive protein are resistance to endotoxemia,”Proc Natl Acad Sci USA, 94:2575-80 (1997).—on CD-ROM.
Jonuleit H, Schmitt E, “The regulatory T cell family:Distinct subsets and threir interrelations,”J. Immun., 171:6323-7 (2003).—on CD-ROM.
Tarzi, RM et al., “Both Fc gamma receptor I and III mediate disease in accelerated nephrotoxic nephritis,”Am. J. Pathol., 162:1677-83
Burlingame RW., et al. “The effect of the acute phase proteins on clearance of chromatin from the circulation of normal mice,”J Immunol. 156:4783-8 (1996).—on CD-ROM.
Mold C., et al., “Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors,”J. Autoimmun, 19:15 147-54 (2002).—on CD-ROM.
Bickerstaff MC., et al., “Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity,”Nat Med, 5:694-7 (1999).—on CD-ROM.
Yin, Z., et al., “IL-10 regulates murine lupus,”J. Immuol., 169:2148-55 (2002).—on CD-ROM.
Samuelsson, A. et al., “Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor,”Science, 291:484-6 (2001).—on CD-ROM.
Kitching AR., et al., “Endogenous interleukin-10 regulates Th 1 responses that induce cresccentic glomerulonephritis,”Kidney Int, 57:518-25 (200).—on CD-ROM.
Groux Het al. A CDA+ Tcell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-42.—on CD-ROM.
Russell, A. I. et al., “Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus,”Human Molecular Genetics, 13(1):137-147 (2004).—CD-ROM.
Du Clos, “C-Reactive Protein as
Du Clos Terry
Mold Carolyn
Coleman Henry D.
Lukton David
Sapone William J.
STC.UNM
Sudol R. Neil
LandOfFree
Use of C-reactive protein to treat immune complex-mediated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of C-reactive protein to treat immune complex-mediated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of C-reactive protein to treat immune complex-mediated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3840456